DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2231558/seeking-clues-to-agilon-agl-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231558 Feb 26, 2024 - Beyond analysts' top -and-bottom-line estimates for Agilon (AGL), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231557/insights-into-cogent-ccoi-q4-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231557 Feb 26, 2024 - Beyond analysts' top -and-bottom-line estimates for Cogent (CCOI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231564/proassurance-pra-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231564 Feb 26, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for ProAssurance (PRA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231560/what-analyst-projections-for-key-metrics-reveal-about-papa-john-s-pzza-q4-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231560 Feb 26, 2024 - Besides Wall Street's top -and-bottom-line estimates for Papa John's (PZZA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231563/ahead-of-everi-holdings-evri-q4-earnings-get-ready-with-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231563 Feb 26, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Everi Holdings (EVRI), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231561/seeking-clues-to-marqeta-mq-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231561 Feb 26, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Marqeta (MQ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231565/countdown-to-goodrx-holdings-inc-gdrx-q4-earnings-wall-street-forecasts-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231565 Feb 26, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for GoodRx Holdings, Inc. (GDRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231570/insights-into-hewlett-packard-enterprise-hpe-q1-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231570 Feb 26, 2024 - Get a deeper insight into the potential performance of Hewlett Packard Enterprise (HPE) for the quarter ended January 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. 0

https://www.zacks.com/stock/news/2231566/stay-ahead-of-the-game-with-dentsply-xray-q4-earnings-wall-street-s-insights-on-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231566 Feb 26, 2024 - Beyond analysts' top -and-bottom-line estimates for Dentsply (XRAY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2231568/countdown-to-pacira-pcrx-q4-earnings-wall-street-forecasts-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2231568 Feb 26, 2024 - Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. 0